Roche sees Herceptin growth rate levelling off

BASEL, Switzerland Jan 30 (Reuters) - Roche Holding AG (ROG.VX) sees a levelling off in growth rates of its cancer drug Herceptin after its fast take-up rate, rather than due to growing competition, its chief executive said.

"Certainly Herceptin has had an uptake that was significantly faster than we expected," Chief Executive Franz Humer told journalists on Wednesday.

(Reporting by Sam Cage)